Posted: February 21st, 2019

Fresenius Kabi AB v/Fresenius Kabi and Fresenius Kabi Oncology Plc. (“Fresenius Kabi”) v. Eli Lilly and Company and Eli Lilly Danmark A/S (“Lilly”), the Danish Eastern High Court, 20 December 2018, Case number B-2735-17 The case concerns the infringement of Lilly’s patent DK/EP 1 313 508 (“DK/EP ‘508”) which relates to the use of the […]


NL – Fast & Fluid Management v. Santint and Zhengzhou Sanhua Technology & Industry

Posted: February 15th, 2019

Fast & Fluid Management B.V. v. Santint B.V. and Zhengzhou Sanhua Technology & Industry Co., Ltd., Judge in interlocutory proceedings, District Court The Hague, The Netherlands, 8 February 2019, Case no. ECLI:NL:RBDHA:2019:1105 Fast & Fluid demanded a preliminary injunction against Santint and Zhengzhou due to alleged infringement on its EP 970 for a ‘valve assembly’. […]


UK – Novartis v. Dr. Reddy’s

Posted: February 5th, 2019

Novartis Pharmaceuticals UK Limited, Novartis Pharma AG & Novartis International Pharmaceutical AG v Dr. Reddy’s Laboratories (UK) Limited, UK Patents Court, 15 January 2019, [2018] EWHC 92 (Pat) In a recent case before the UK Patents Court, in addition to considering an application for summary judgment to revoke the patent in suit for added matter, […]


NL – Koninklijke Douwe Egberts v. Belmoca

Posted: January 30th, 2019

Koninklijke Douwe Egberts B.V. v. Belmoca BVBA, Interlocutory Judge of the District Court of The Hague, The Netherlands, 28 December 2018, Case No. ECLI:NL:RBDHA:2018:15453 Nespresso compatible coffee capsules. Koninklijke Douwe Egberts (hereafter: KDE) accuses Belmoca of indirect infringement of EP 521 relating to ‘A beverage preparation system, a capsule and a method for forming a […]


FR – Novartis v. Teva – Valsartan / Amlodipine – € 13,000,000 advance on damages

Posted: June 11th, 2018

Preliminary injunction issued by a French court against Teva’s generic of Novartis’ Exforge anti-hypertensive drug (valsartan/amlodipine) plus €13,000,000 awarded as an advance on damages On 7 June 2018, the tribunal de grande instance of Paris (Judge Marie Courboulay) issued a preliminary injunction against Teva’s generic of Novartis’ anti-hypertensive drug Exforge (valsartan/amlodipine) on the basis of […]


AT – Eli Lilly PI / Appeal

Posted: April 27th, 2018

Austrian Court of Appeals confirms PI based on equivalent infringement of Eli Lilly’s Alimta®-Patent In a decision of April 12th 2018, the Vienna Court of Appeals rejected an appeal against a preliminary injunction previously granted by the Vienna Commercial Court. The Court of Appeals confirmed that the offer or sale of a generic Pemetrexed product […]


SE – Sandoz v. ViiV Healthcare

Posted: March 2nd, 2018

Sandoz A/S v. ViiV Healthcare UK Limited, Patent and Market Court of Appeal, Sweden, 30 June 2017, Docket No. PMÖ 3565-17 Sandoz requested that the preliminary injunction barring its pharmaceutical products Abacavir/Limavudine Sandoz 600 mg/300 mg from being marketed and sold on the Swedish market be vacated. The Patent and Market Court of Appeal overturned […]


ES – Gilead v. Teva & Mylan / Tenofovir + Emtricitabine / Interim injunction opposition

Posted: February 7th, 2018

Gilead Biopharmaceutics Ireland UC., Gilead Sciences, S.L.U., Gilead Sciences Ireland UC., Gilead Sciences, Inc. v. Teva Pharma, S.L.U, Mylan Pharmaceuticals, S.L., Mylan S.A.S., Barcelona Commercial Court No. 4, 20 October 2017, Docket No. 190/2017 – 197/17 In its decision of 20 October 2017, Barcelona Commercial Court No. 4 reversed its previous rulings pursuant to which […]


NL – Sandoz v. Astrazeneca / Appeal

Posted: November 2nd, 2017

Sandoz B.V. v. Astrazeneca AB, Court of Appeal The Hague, The Netherlands, 31 October 2017, Case No. 200.200.332/01, with thanks to Willem Hoyng and Theo Blomme, HOYNG ROKH MONEGIER, for submitting the case including an English and German translation thereof Astrazeneca markets FASLODEX which is used for the treatment of oestrogen hormone dependent breast cancers. […]